Processa Pharmaceuticals, Inc. (PCSA) Bundle
An Overview of Processa Pharmaceuticals, Inc. (PCSA)
General Summary of Processa Pharmaceuticals, Inc. (PCSA)
Processa Pharmaceuticals, Inc. (PCSA) is a clinical-stage pharmaceutical company focused on developing innovative drug therapies for cancer and other related conditions. Founded in 2017, the company has a pipeline that includes several oncology-focused candidates, notably NGC-Cap, which is undergoing clinical trials for breast cancer treatment. As of 2024, Processa has not yet generated any product revenue, as its drug candidates are still in various stages of clinical development.
In 2024, Processa has seen a notable increase in its activity, particularly with the initiation of a Phase 2 trial for NGC-Cap, which demonstrates the company's commitment to advancing its therapeutic offerings. The company's focus remains on leveraging its research and development capabilities to bring new treatments to market, addressing unmet medical needs in oncology.
As of 2024, Processa Pharmaceuticals reported cash and cash equivalents totaling approximately $2.9 million, indicating a need for additional funding to support ongoing operations and clinical trials.
Company's Financial Performance in the Latest Financial Reports
In its latest financial reports for the nine months ended September 30, 2024, Processa Pharmaceuticals recorded a net loss of $9.12 million, compared to a net loss of $8.72 million for the same period in 2023. This reflects an increase in operating expenses primarily due to the costs associated with the clinical trials for its drug candidates. The total operating loss for the period was approximately $9.32 million.
Research and development expenses surged to $5.56 million for the nine months ended September 30, 2024, an increase from $4.48 million in the prior year. This increase is attributed to heightened activity in clinical trials, particularly for NGC-Cap.
Financial highlights from the latest reporting period include:
| Metric | Q3 2024 | Q3 2023 |
|---|---|---|
| Net Loss | $3,384,703 | $2,081,951 |
| Net Loss per Share | $1.03 | $1.54 |
| Research and Development Expenses | $5,556,694 | $4,478,793 |
| General and Administrative Expenses | $3,759,781 | $4,508,818 |
| Cash and Cash Equivalents | $2,891,464 | $6,860,672 |
Additionally, Processa raised net proceeds of approximately $6.3 million from a public offering on January 30, 2024, which included the sale of 476,000 shares of common stock. The company also generated approximately $931,000 from its ATM offering in July 2024.
Processa as a Leader in the Industry
Processa Pharmaceuticals is positioned as a promising player in the oncology pharmaceutical sector, focusing on underserved patient populations. With a dedicated pipeline targeting various cancer therapies, the company aims to leverage its clinical trial outcomes to establish itself as a market leader in innovative cancer treatments. The significant investments in research and development, along with strategic fundraising efforts, reflect a robust commitment to advancing its therapeutic candidates.
Investors and stakeholders are encouraged to explore further insights into Processa Pharmaceuticals to understand its strategic direction and the potential impact of its innovative therapies on patient care and the oncology market at large.
Mission Statement of Processa Pharmaceuticals, Inc. (PCSA)
Mission Statement of Processa Pharmaceuticals, Inc. (PCSA)
Processa Pharmaceuticals, Inc. (PCSA) is committed to developing and delivering innovative therapies for patients with unmet medical needs, particularly in oncology. The mission statement emphasizes the company's dedication to enhancing patient outcomes through its robust pipeline of next-generation chemotherapy drug candidates.
The significance of a mission statement lies in its ability to guide the company's long-term goals, ensuring that all efforts align with its core purpose. For Processa Pharmaceuticals, this involves a focus on rigorous research and development, strategic partnerships, and a commitment to quality and safety in all product offerings.
Core Component 1: Innovation
Innovation is a cornerstone of Processa's mission, driving the development of new therapeutic options. The company focuses on leveraging advanced technologies to create drugs that improve efficacy and reduce side effects. For instance, the ongoing Phase 2 trial for NGC-Cap aims to enhance treatment for breast cancer patients, reflecting the company's innovative approach to addressing specific medical challenges.
Core Component 2: Patient-Centric Focus
Processa Pharmaceuticals places a strong emphasis on patient needs and outcomes. The mission statement highlights the importance of understanding patient experiences and incorporating their feedback into the drug development process. This patient-centric philosophy is evident in the design of clinical trials, which aim to ensure that therapies meet the actual needs of patients.
Core Component 3: Commitment to Quality
Quality assurance is essential in the pharmaceutical industry, and Processa Pharmaceuticals is dedicated to maintaining high standards throughout its operations. The mission statement reflects this commitment by emphasizing the importance of safety and efficacy in all products. The company adheres to stringent regulatory guidelines and quality control measures to ensure that its therapies meet the highest standards before reaching the market.
| Financial Metrics | Q3 2024 | Q3 2023 | Change |
|---|---|---|---|
| Net Loss | $3,384,703 | $2,081,951 | $1,302,752 |
| Accumulated Deficit | $84,490,491 | $72,964,150 | $11,526,341 |
| Research and Development Expenses | $5,556,694 | $4,478,793 | $1,077,901 |
| Cash and Cash Equivalents | $2,891,464 | $6,860,672 | ($3,969,208) |
As of September 30, 2024, Processa Pharmaceuticals reported a net loss of $3,384,703, an increase from $2,081,951 in the same quarter of the previous year. The accumulated deficit has risen to $84,490,491, indicating ongoing investment in research and development, which totaled $5,556,694 for the nine months ended September 30, 2024.
Vision Statement of Processa Pharmaceuticals, Inc. (PCSA)
Vision Statement Overview
The vision statement of Processa Pharmaceuticals, Inc. (PCSA) emphasizes the commitment to innovation and the development of next-generation therapies aimed at improving patient outcomes. As of 2024, the company focuses on advancing its pipeline of oncology products, particularly NGC-Cap, while maintaining a strong emphasis on ethical practices and stakeholder engagement.
Commitment to Innovation
Processa Pharmaceuticals aims to be at the forefront of pharmaceutical innovation. The company is dedicated to developing new treatments for unmet medical needs, particularly in oncology. As of September 30, 2024, the company reported a net loss of $9.1 million, reflecting its ongoing investment in research and development activities.
Focus on Oncology
The primary focus of Processa Pharmaceuticals is on its oncology pipeline, specifically the development of NGC-Cap. The company has initiated its Phase 2 trial for NGC-Cap in breast cancer, which commenced in October 2024. The total research and development costs for the nine months ended September 30, 2024, were approximately $5.6 million, a significant increase from the prior year, indicating a robust commitment to advancing its clinical trials.
Ethical Practices and Stakeholder Engagement
Processa Pharmaceuticals is dedicated to ethical practices in all aspects of its operations. The company actively engages with stakeholders, including investors, healthcare professionals, and patients, to ensure transparency and accountability. The accumulated deficit stood at $84.5 million as of September 30, 2024, highlighting the financial challenges faced while striving to fulfill its vision.
| Financial Metric | Q3 2024 | Q3 2023 | Change |
|---|---|---|---|
| Net Loss | $9,121,410 | $8,716,589 | $404,821 |
| Research and Development Expenses | $5,556,694 | $4,478,793 | $1,077,901 |
| Cash and Cash Equivalents | $2,891,464 | $6,860,672 | Decrease |
| Accrued Expenses | $266,539 | ($200,825) | Increase |
Future Aspirations
Looking ahead, Processa Pharmaceuticals aims to secure additional funding to support its ongoing clinical trials and research efforts. The company anticipates increased clinical trial costs as it progresses with its drug candidates. The planned financing activities include an at-the-market offering potentially raising up to $50 million.
Core Values of Processa Pharmaceuticals, Inc. (PCSA)
Integrity
Integrity is a fundamental value at Processa Pharmaceuticals, Inc. (PCSA). It underscores the importance of ethical conduct and transparency in all aspects of the business. This commitment to integrity is reflected in the company’s adherence to regulatory standards and its dedication to maintaining trust with stakeholders.
For instance, in 2024, Processa reported an accumulated deficit of $84.5 million, highlighting the financial challenges faced while emphasizing the importance of ethical decision-making in resource allocation and operational transparency.
Innovation
Innovation drives Processa’s mission to develop next-generation cancer therapies. The company invests significantly in research and development, with expenses totaling $5.56 million for the nine months ended September 30, 2024, compared to $4.48 million in the same period of 2023.
Specific innovations include the initiation of the Phase 2 clinical trial for NGC-Cap in breast cancer, which began dosing patients on October 2, 2024. This trial is a pivotal step in the company's efforts to bring new therapies to market.
Collaboration
Collaboration is vital to Processa’s approach, fostering partnerships that enhance its research capabilities. The company works closely with contract research organizations (CROs), committing up to $13 million for future services under these contracts.
Additionally, Processa's strategic partnerships with entities like CorLyst, which reimburses shared costs, further exemplify the importance of collaboration in achieving mutual goals.
Accountability
Accountability is central to Processa’s operations, ensuring that all team members are responsible for their actions and decisions. For the nine months ended September 30, 2024, the company reported a net loss of $9.12 million, necessitating a thorough review of spending and operational efficiency.
Furthermore, the appointment of a new Chief Financial Officer in July 2024 demonstrates the company's commitment to strong financial governance and oversight.
Excellence
Excellence is a core value that Processa strives for in all its endeavors. The company aims to maintain high standards in its research processes and clinical trials. The recent approval of the IND for its Phase 2 trial signifies a commitment to excellence in regulatory compliance and scientific rigor.
Moreover, the company's ongoing investment in its workforce, exemplified by a $400,000 annual salary for the new CFO, reflects its commitment to attracting top talent and fostering a culture of excellence.
| Core Value | Importance | Recent Example | Financial Impact |
|---|---|---|---|
| Integrity | Ethical conduct and transparency | Accumulated deficit of $84.5 million | Impacts financial decisions |
| Innovation | Development of next-generation therapies | Phase 2 trial for NGC-Cap initiated | $5.56 million R&D expenses |
| Collaboration | Enhancing research through partnerships | Partnership with CROs | $13 million committed for services |
| Accountability | Responsibility for actions and decisions | Net loss of $9.12 million reported | Review of spending required |
| Excellence | Maintaining high standards | IND approval for Phase 2 trial | $400,000 CFO salary reflects commitment |
Processa Pharmaceuticals, Inc. (PCSA) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Article updated on 8 Nov 2024
Resources:
- Processa Pharmaceuticals, Inc. (PCSA) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of Processa Pharmaceuticals, Inc. (PCSA)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View Processa Pharmaceuticals, Inc. (PCSA)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.